# A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer

> **NCT00564928** · PHASE2 · COMPLETED · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Prostate Cancer
- Prostatic Neoplasms
- Cancer of the Prostate

## Interventions

- **DRUG:** IPI-504

## Key facts

- **NCT ID:** NCT00564928
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-03
- **Final completion:** 2010-07
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2012-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00564928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00564928, "A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00564928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*